News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Apthera, Inc. Announces Phase III and Commercial Drug Formulation for NeuVax(TM)



12/9/2008 8:33:18 AM

SCOTTSDALE, AZ--(Marketwire - December 09, 2008) - Apthera, Inc., a biotechnology company focused on peptide-based cancer immunotherapy, today announced that it has determined to go forward with a lyophilized form of the E75 peptide component of its NeuVax product. This commercially viable formulation will provide the Company a stable drug product to conduct worldwide Phase III clinical trials and prepare for commercial sales.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES